Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells

Hemant Kulkarni, Harald H H Göring, Joanne E. Curran, Vincent Diego, Thomas D. Dyer, Shelley Cole, Ken R. Walder, Greg R. Collier, John Blangero, Melanie A. Carless

Research output: Contribution to journalArticle

Abstract

Purpose: The role of v-ATPases in cancer biology is being increasingly recognized. Yeast studies indicate that the tyrosine kinase inhibitor imatinib may interact with the v-ATPase genes and alter the course of cancer progression. Data from humans in this regard are lacking. Methods: We constructed 55 lymphoblastoid cell lines from pedigreed, cancer-free human subjects and treated them with IC20 concentration of imatinib mesylate. Using these cell lines, we (i) estimated the heritability and differential expression of 19 genes encoding several subunits of the v-ATPase protein in response to imatinib treatment; (ii) estimated the genetic similarity among these genes; and (iii) conducted a high-density scan to find cis-regulating genetic variation associated with differential expression of these genes. Results: We found that the imatinib response of the genes encoding v-ATPase subunits is significantly heritable and can be clustered to identify novel drug targets in imatinib therapy. Further, five of these genes were significantly cis-regulated and together represented nearly half-log fold change in response to imatinib (p = 0.0107) that was homogenous (p = 0.2598). Conclusions: Our results proffer support to the growing view that personalized regimens using proton pump inhibitors or v-ATPase inhibitors may improve outcomes of imatinib therapy in various cancers.

Original languageEnglish (US)
Pages (from-to)1095-1100
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume71
Issue number4
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Vacuolar Proton-Translocating ATPases
Proton-Translocating ATPases
Genes
Adenosine Triphosphatases
Gene encoding
Neoplasms
Cells
Gene Expression
Cell Line
Proton Pump Inhibitors
Imatinib Mesylate
Yeast
Protein-Tyrosine Kinases
Yeasts
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chronic myeloid leukemia
  • Imatinib
  • Metastasis
  • Microarray

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells. / Kulkarni, Hemant; Göring, Harald H H; Curran, Joanne E.; Diego, Vincent; Dyer, Thomas D.; Cole, Shelley; Walder, Ken R.; Collier, Greg R.; Blangero, John; Carless, Melanie A.

In: Cancer Chemotherapy and Pharmacology, Vol. 71, No. 4, 04.2013, p. 1095-1100.

Research output: Contribution to journalArticle

Kulkarni, H, Göring, HHH, Curran, JE, Diego, V, Dyer, TD, Cole, S, Walder, KR, Collier, GR, Blangero, J & Carless, MA 2013, 'Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells', Cancer Chemotherapy and Pharmacology, vol. 71, no. 4, pp. 1095-1100. https://doi.org/10.1007/s00280-013-2110-4
Kulkarni, Hemant ; Göring, Harald H H ; Curran, Joanne E. ; Diego, Vincent ; Dyer, Thomas D. ; Cole, Shelley ; Walder, Ken R. ; Collier, Greg R. ; Blangero, John ; Carless, Melanie A. / Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells. In: Cancer Chemotherapy and Pharmacology. 2013 ; Vol. 71, No. 4. pp. 1095-1100.
@article{b1139f7d81ac45389f718fa7e739cded,
title = "Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells",
abstract = "Purpose: The role of v-ATPases in cancer biology is being increasingly recognized. Yeast studies indicate that the tyrosine kinase inhibitor imatinib may interact with the v-ATPase genes and alter the course of cancer progression. Data from humans in this regard are lacking. Methods: We constructed 55 lymphoblastoid cell lines from pedigreed, cancer-free human subjects and treated them with IC20 concentration of imatinib mesylate. Using these cell lines, we (i) estimated the heritability and differential expression of 19 genes encoding several subunits of the v-ATPase protein in response to imatinib treatment; (ii) estimated the genetic similarity among these genes; and (iii) conducted a high-density scan to find cis-regulating genetic variation associated with differential expression of these genes. Results: We found that the imatinib response of the genes encoding v-ATPase subunits is significantly heritable and can be clustered to identify novel drug targets in imatinib therapy. Further, five of these genes were significantly cis-regulated and together represented nearly half-log fold change in response to imatinib (p = 0.0107) that was homogenous (p = 0.2598). Conclusions: Our results proffer support to the growing view that personalized regimens using proton pump inhibitors or v-ATPase inhibitors may improve outcomes of imatinib therapy in various cancers.",
keywords = "Chronic myeloid leukemia, Imatinib, Metastasis, Microarray",
author = "Hemant Kulkarni and G{\"o}ring, {Harald H H} and Curran, {Joanne E.} and Vincent Diego and Dyer, {Thomas D.} and Shelley Cole and Walder, {Ken R.} and Collier, {Greg R.} and John Blangero and Carless, {Melanie A.}",
year = "2013",
month = "4",
doi = "10.1007/s00280-013-2110-4",
language = "English (US)",
volume = "71",
pages = "1095--1100",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells

AU - Kulkarni, Hemant

AU - Göring, Harald H H

AU - Curran, Joanne E.

AU - Diego, Vincent

AU - Dyer, Thomas D.

AU - Cole, Shelley

AU - Walder, Ken R.

AU - Collier, Greg R.

AU - Blangero, John

AU - Carless, Melanie A.

PY - 2013/4

Y1 - 2013/4

N2 - Purpose: The role of v-ATPases in cancer biology is being increasingly recognized. Yeast studies indicate that the tyrosine kinase inhibitor imatinib may interact with the v-ATPase genes and alter the course of cancer progression. Data from humans in this regard are lacking. Methods: We constructed 55 lymphoblastoid cell lines from pedigreed, cancer-free human subjects and treated them with IC20 concentration of imatinib mesylate. Using these cell lines, we (i) estimated the heritability and differential expression of 19 genes encoding several subunits of the v-ATPase protein in response to imatinib treatment; (ii) estimated the genetic similarity among these genes; and (iii) conducted a high-density scan to find cis-regulating genetic variation associated with differential expression of these genes. Results: We found that the imatinib response of the genes encoding v-ATPase subunits is significantly heritable and can be clustered to identify novel drug targets in imatinib therapy. Further, five of these genes were significantly cis-regulated and together represented nearly half-log fold change in response to imatinib (p = 0.0107) that was homogenous (p = 0.2598). Conclusions: Our results proffer support to the growing view that personalized regimens using proton pump inhibitors or v-ATPase inhibitors may improve outcomes of imatinib therapy in various cancers.

AB - Purpose: The role of v-ATPases in cancer biology is being increasingly recognized. Yeast studies indicate that the tyrosine kinase inhibitor imatinib may interact with the v-ATPase genes and alter the course of cancer progression. Data from humans in this regard are lacking. Methods: We constructed 55 lymphoblastoid cell lines from pedigreed, cancer-free human subjects and treated them with IC20 concentration of imatinib mesylate. Using these cell lines, we (i) estimated the heritability and differential expression of 19 genes encoding several subunits of the v-ATPase protein in response to imatinib treatment; (ii) estimated the genetic similarity among these genes; and (iii) conducted a high-density scan to find cis-regulating genetic variation associated with differential expression of these genes. Results: We found that the imatinib response of the genes encoding v-ATPase subunits is significantly heritable and can be clustered to identify novel drug targets in imatinib therapy. Further, five of these genes were significantly cis-regulated and together represented nearly half-log fold change in response to imatinib (p = 0.0107) that was homogenous (p = 0.2598). Conclusions: Our results proffer support to the growing view that personalized regimens using proton pump inhibitors or v-ATPase inhibitors may improve outcomes of imatinib therapy in various cancers.

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Metastasis

KW - Microarray

UR - http://www.scopus.com/inward/record.url?scp=84878859484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878859484&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2110-4

DO - 10.1007/s00280-013-2110-4

M3 - Article

C2 - 23420437

AN - SCOPUS:84878859484

VL - 71

SP - 1095

EP - 1100

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -